Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Anavex Life Sciences (AVXL)

Biological Products, (no Disgnostic Substances)

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

630 5TH AVENUE, 20TH FLOOR
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/02/2006

Market Cap

516,421,554

Shares Outstanding

82,090,000

Weighted SO

82,086,511

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

SAVA --.--%

INMB --.--%

BIVI --.--%

CGTX --.--%

ANVS --.--%

IOVA --.--%

AXSM --.--%

NVAX --.--%

EXEL --.--%

Beta

0.6320

Last Div

0.0000

Range

3.25-10.45

Chg

-0.2198

Avg Vol

1190080

Mkt Cap

516421554

Exch

NASDAQ

Country

US

Phone

844 689 3939

DCF Diff

4.1672

DCF

1.8928

Div Yield

0.0000

P/S

0.0000

EV Multiple

-7.7516

P/FV

3.9642

Div Yield %

0.0000

P/E

-12.3973

PEG

-3.8432

Payout

0.0000

Current Ratio

12.0414

Quick Ratio

12.0414

Cash Ratio

11.8050

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.0221

ROA

-0.2932

ROE

-0.3062

ROCE

-0.3730

NI/EBT

0.9779

EBT/EBIT

0.8767

EBIT/Rev

0.0000

Debt Ratio

-0.0065

D/E

-0.0071

LT Debt/Cap

0.0000

Total Debt/Cap

-0.0071

Int Coverage

140805.7820

CF/Debt

32.7193

Equity Multi

1.0905

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.3549

FCF/Share

-0.3549

Cash/Share

1.6414

OCF/Sales

0.0000

FCF/OCF

1.0000

CF Coverage

32.7193

ST Coverage

32.7193

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

3.9642

P/B

3.9642

P/S

0.0000

P/E

-12.3973

P/FCF

-17.2120

P/OCF

-17.1592

P/CF

-17.1592

PEG

-3.8432

P/S

0.0000

EV Multiple

-7.7516

P/FV

3.9642

DPS

0.0000

Latest Headlines (EST)

Benzinga Nov 08, 23:28 Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? GlobeNewswire Inc. Jul 28, 21:00 Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference GlobeNewswire Inc. Jan 16, 07:30 Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia GlobeNewswire Inc. Jan 08, 07:30 Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders GlobeNewswire Inc. Jan 03, 07:30 Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 20, 07:30 Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome GlobeNewswire Inc. Dec 19, 07:30 Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease Benzinga Nov 27, 13:41 Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Revenue Product Segmentation